Use: Labeled indications
- The treatment of edema associated with heart failure, cirrhosis of the liver, and renal disease
- Acute pulmonary edema as adjunctive therapy
Full indications and usage US FDA label
1 INDICATIONS AND USAGE Furosemide injection is a loop diuretic indicated for: The treatment of edema associated with heart failure, cirrhosis of the liver, and renal disease (1.1) Acute pulmonary edema as adjunctive therapy (1.2) 1.1 Edema Furosemide injection is indicated in adults and pediatric patients for the treatment of edema associated with heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. 1.2 Acute Pulmonary Edema Furosemide injection is indicated as adjunctive therapy in acute pulmonary edema.
Contraindications
4 CONTRAINDICATIONS Furosemide injection is contraindicated in patients with anuria. Furosemide injection is contraindicated in patients with a history of hypersensitivity to furosemide. Anuria (4) Hypersensitivity to furosemide (4)
US FDA labelDosing: Adult
- Edema: Initial dose is 20 mg to 40 mg once given intramuscularly or intravenously. The intravenous dose should be administered slowly over 1 minute to 2 minutes (2.2)
- If needed, a second dose may be administered 2 hours after the first dose (2.2)
- May be administered as a continuous intravenous infusion at a rate not greater then 4 mg/min (2.2)
- Acute Pulmonary Edema: Initial dose is 40 mg injected slowly intravenously over 1 minute to 2 minutes (2.2)
- If needed, a second dose is 80 mg injected intravenously slowly over 1 minute to 2 minutes may be given after 1 hour (2.2)
- Pediatric Dosage: The initial dose in pediatric patients is 1 mg/kg body weight once given slowly intramuscularly or intravenously. If needed, dosage may be increased by 1 mg/kg not sooner than 2 hours after the previous dose, until the desired diuretic effect has been obtained. Doses greater than 6 mg/kg body weight are not recommended (2.3)
2.1 General Considerations
2.1 General Considerations Inspect Furosemide injection visually for particulate matter and discoloration before administration. Discard unused portion.
2.2 Recommended Dosage for Adults Edema
2.2 Recommended Dosage for Adults Edema Individualize therapy according to patient response. The usual initial dose of furosemide is 20 mg to 40 mg given as a single-dose, injected intramuscularly or intravenously. Give the intravenous dose slowly (over 1 minute to 2 minutes). If needed, administer another dose in the same manner 2 hours later or increase the dose.
The dose may be raised by 20 mg and administered not sooner than 2 hours after the previous dose until the desired diuretic effect has been obtained. Administer this individually determined single-dose once or twice daily. Furosemide may also be administered via continuous intravenous infusion at a rate not greater than 4 mg/min.
Acute Pulmonary Edema The usual initial dose of furosemide is 40 mg injected slowly intravenously (over 1 minute to 2 minutes). If a satisfactory response does not occur within 1 hour, increase the dose to 80 mg injected slowly intravenously (over 1 minute to 2 minutes).
2.3 Recommended Dosage for Pediatric Patients
2.3 Recommended Dosage for Pediatric Patients The usual initial dose of Furosemide injection (intravenously or intramuscularly) in pediatric patients is 1 mg/kg body weight administered slowly (over 1 minute to 2 minutes). If the diuretic response to the initial dose is not satisfactory, dosage may be increased by 1 mg/kg not sooner than 2 hours after the previous dose, until the desired diuretic effect has been obtained.
Doses greater than 6 mg/kg body weight are not recommended. The maximum dose for premature infants should not exceed 1 mg/kg/day [see Use in Specific Populations (8.4)].
Dosing: Altered kidney function
Patients with Renal Impairment One study in six subjects demonstrated that the combination of furosemide and acetylsalicylic acid temporarily reduced creatinine clearance in patients with chronic renal insufficiency. There are case reports of patients who developed increased BUN, serum creatinine and serum potassium levels, and weight gain when furosemide was used in conjunction with NSAIDs.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use Published reports indicate that premature infants with post conceptual age (gestational plus postnatal) less than 31 weeks receiving doses exceeding 1 mg/kg/24 hours may develop plasma levels which could be associated with potential toxic effects including ototoxicity [see Warnings and Precautions (5.3)]. Furosemide in the first year of life, especially in patients born pre-term, may precipitate nephrocalcinosis/nephrolithiasis [see Warnings and Precautions (5.2)].
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Controlled clinical studies of furosemide did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for the elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.
This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function [see Clinical Pharmacology (12.3)].
Dosage forms
Philippines
- ) solution for injection: 10 mg/mL (20 mg/2 mL, 10 mg/mL (20 mg/mL
- Solution for injection: 10 mg/mL, 20 mg/2 mL
- Tablet: 20 mg, 40 mg
- Film-coated tablet: 40 mg
- Solution for inject: 10 mg/mL
- Solution for injection (im/iv: 10 mg/mL
Registered products in the Philippines
87 products registered with the Food and Drug Administration (FDA) Philippines list Furosemide as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products87
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AefurFurosemide | 10 mg/mL (20 mg/ 2mL) Solution for Injection (I.M./I.V.)2 mL Type I Amber glass ampoule with plastic tray (Box of 10's) | RxVAT-exempt | Siu Guan Chem, Ind. Co., Ltd.Taiwan | Caan Pharmaceutical Co., Inc. | DRP-10987 | Dec 28, 2026 | |
AerufFurosemide | 10 mg/mL (20 mg/2 mL) Solution for Injection (I.M./I.V.)Brown Low Borosilicate Glass Ampoule x 2 mL (net content) (Box of 10's) | RxVAT-exempt | Furen Pharmaceutical Group Co., Ltd.China | Dynasty PharmaceuticalsImporter: Euro-Care Products Philippines | DRP-8351-07 | Aug 22, 2029 | |
AldicFurosemide | 10 mg/ mL (20 mg/2 mL) Solution for Injection (IM/IV)USP Type I amber colored ampoule x 2ml Box of 50's | RxVAT-exempt | T.P. Drug Laboratories (1969) Co., Ltd.Thailand | Lordla Pharma Sales | DR-XY32598 | Aug 3, 2027 | |
DimideFurosemide | 40 mg TabletAlu/Clear PVC Blister Pack x 10’s (Box of 100's) | RxVAT-exempt | West Coast Pharmaceutical Works Ltd.India | Bell-Kenz Pharma Inc.Importer: Ambica International Corporation | DRP-6138 | May 6, 2030 | |
DioventFurosemide | 10 mg/mL (20 mg/ 2mL) Solution for Injection (I.V./I.M.)USP Type I Amber coloured glass ampoule x 2 mL (Box of 10's) | RxVAT-exempt | Makcur Laboratories LimitedIndia | Bliss Pharma Distribution and Consultancy Corp.Importer: Afree Pharmaceutical Distribution Corp. | DRP-14389-03 | Aug 31, 2028 | |
DiufedFurosemide | 10 mg/mL (20mg/2mL) Solution for Injection (I.M./I.V.)Brown Low Borosilicate Glass Ampoule x 2 mL (net content) (Box of 10's) | RxVAT-exempt | Furen Pharmaceutical Group Co., Ltd.China | Federal Pharmaceuticals Inc.Importer: Euro-Care Products Philippines | DRP-8351-05 | Aug 22, 2029 | |
DiulixFurosemide | 10 mg/mL (20 mg/2 mL) Solution for Injection (I.M./I.V.)USP Type I Amber Colored Glass Ampoule x 2 mL (Box of 10's) | RxVAT-exempt | Harmann Pharmaceutical Laboratories (Pvt) Ltd.Pakistan | Exa Life Care Pharma Inc.Importer: Raquel-Abbas Pharmaceuticals & General Merchandise | DRP-4423-02 | Sep 11, 2031 | |
DiurmedFurosemide | 40mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100‘s) | RxVAT-exempt | MAGBRO HEALTHCARE PVT. LTD.India | TERAMEDIX PHARMA TRADING INC. | DRP-14197 | Jul 18, 2028 | |
DiuspecFurosemide | 10 mg/mL Solution for Injection (IV/IM)USP Type II Amber Glass Ampoule x 2 mL (Box of 20’s) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | Trader: Pharmaspec N.A., Inc. | DR-XY32774 | Dec 21, 2031 | |
DiuspecFurosemide | 20 mg TabletFoil Strip x 4’s (Box of 100’s) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | Trader: Pharmaspec N.A., Inc. | DR-XY27839 | Nov 12, 2029 | |
DiuspecFurosemide | 40 mg TabletAluminum Foil Strip x 4’s (Box of 100’s) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | Trader: Pharmaspec N.A. Inc. | DR-XY28817 | Jul 24, 2028 | |
EdecarFurosemide | 10 mg/mL Solution for Injection (IM/IV)USP Type 1 Amber Glass Ampoule x 2 mL (Box of 10’s) | RxVAT-exempt | Umedica Laboratories Pvt. Ltd.India | Suhitas Pharmaceuticals Inc. | DRP-6165 | Feb 24, 2031 | |
EdemannFurosemide | 40 mg TabletAlu-Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Yu Sheng Pharmaceutical Co.Taiwan | Littman Drug Corporation | DR-XY25904 | Feb 4, 2030 | |
FeroblesFurosemide | 10 mg/mL (20 mg/2mL) Solution For Injection (I.V./I.M.)USP Type I Amber coloured glass ampoule x 2mL (Box of 10's) | RxVAT-exempt | Makcur Laboratories LimitedIndia | Afree Pharmaceutical Distribution CorpImporter: Afree Pharmaceutical Distribution Corp. | DRP-14389 | Aug 31, 2028 | |
FosemFurosemide | 10 mg/mL (20 mg/2 mL) Solution For Injection (IM/IV) | RxVAT-exempt | Psychotropics India Limited (General Block)India | Despina Pharma Inc. | DRP-17735 | Feb 23, 2031 | |
FremidFurosemide | 10 mg/mL Solution for Injection (IV/IM)Low Density Polyethylene Ampoule (LDPE) in foil pouch (5 x 2 mL) (Box of 30's) | RxVAT-exempt | Euro-Med Laboratories Phil., Inc.Philippines | — | DR-XY 29579 | May 4, 2029 | |
FrosemFurosemide | 10 mg/mL (20 Mg/Ml) Solution for Injection (IM/IV)Type I Low Borosilicate Amber Glass Ampoule X 2 Ml (Box of 10’S) | RxVAT-exempt | Anhui Changjiang Pharmaceutical Co., Ltd.China | Central West Medicale Inc.Importer: Aglobal Care, Inc. | DRP-6647-04 | Jan 9, 2030 | |
FrosiFurosemide | 10 mg/mL (20 mg/mL) Solution For Injection (IM/IV)Type I Low Borosilicate Amber Glass Ampoule x 2 mL (Box of 10’s) | RxVAT-exempt | Anhui Changjiang Pharmaceutical Co., Ltd.China | Bellus Life Solutions, Inc.Importer: Aglobal Care, Inc. | DRP-6647-02 | Jan 9, 2030 | |
FrudisFurosemide | 10 mg/ mL Solution For Injection (IM/IV)Amber glass ampoule x 2mL (Box of 2 blister pack x 5 ampoules) | RxVAT-exempt | Sakar Healthcare Pvt. Ltd.India | Macropharma Corporation | DRP-12586 | Sep 12, 2027 | |
FrusemaFurosemide | 10 mg/mL (20 mg/2 mL) Solution for Injection (IM/IV)Amber Glass Ampoule x 2 mL (Box of 10's) | RxVAT-exempt | Amherst Parenterals, Inc.Philippines | Trader: Ritemed Phils., Inc. | DR-X885 | Oct 14, 2027 | |
FrusemaFurosemide | 20 mg TabletAlu-PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Am-Europharma CorporationPhilippines | Ritemed Phils., Inc. | DRP-2892-02 | Apr 11, 2027 | |
FrusemaFurosemide | 40 mg TabletAlu-PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | AM-Europharma CorporationPhilippines | Trader: Ritemed Phils., Inc. | DR-XY40711 | Mar 2, 2027 | |
FrusemideFurosemide | 10 mg/ mL (20 mg/ 2 mL) Solution for Injection (I.M./I.V.)USP Type I Amber Glass Ampoule x 2 mL (Box of 10's) | RxVAT-exempt | CSPC Ouyi Pharmaceutical Co. Ltd.China | AMB HK Enterprises Inc. | DRP-8097 | Jun 26, 2028 | |
FuminovFurosemide | 10 mg/mL Solution For Injection (I.M./I.V.)2 mL USP Type I amber glass ampoule in PVC tray (Box of 5’s, 10’s & 25’s) | RxVAT-exempt | Skymap Healthcare Pvt. Ltd.India | Medinova Pharmaceutical Inc. | DRP-19086 | Oct 27, 2031 | |
FurideFurosemide | 10 mg/mL (20 mg/2 mL) Solution For Injection (IV/IM)USP Type I Amber Glass Ampoule x 2 mL Box of 10's | RxVAT-exempt | Gland Pharma LimitedIndia | Endure Medical, Inc. | DR-XY42946 | Nov 13, 2028 | |
FurixFurosemide | 40 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Basic Pharmaceutical Corp. | DR-XY20491 | Oct 20, 2028 | |
FurmidFurosemide | 10 mg/mL (20 mg / 2 mL) Solution for Injection (I.M./I.V.)USP Type I Clear Amber colored glass ampoule x 2 mL wrapped in Alu/PVC blister pack x 5's (Box of 10's) | RxVAT-exempt | Global Pharmaceuticals (Pvt) Ltd.Pakistan | Surestep Pharmaceuticals, Inc. | DR-XY48892 | Oct 3, 2028 | |
Furo-LFurosemide (as sodium) | 10 mg/mL Solution for Injection (IM/IV)Clear Glass Ampoule x 2 mL (Box of 10 ampoules in PVC tray) | RxVAT-exempt | Pharmax India Private Limited.India | Wellchem Pharmaceutical ProductsTrader: Keshavial Vejechand | DRP-15372 | Jun 28, 2029 | |
FurodenFurosemide | 10 mg/ mL Solution for Injection (IM/IV)USP Type I amber glass ampoule x 2 mL (Box of 5 ampoules x 2 mL; Box of 10 ampoules x 2mL) | RxVAT-exempt | Farbe FirmaIndia | Cyden Medicale Trading Inc.Importer: AMB HK Enterprises Inc.Trader: Medicon Lifesciences | DRP-12524-01 | Aug 26, 2027 | |
FurogemFurosemide | 10 mg/mL (20 mg/2mL) Solution for Injection (IM/IV)Type I Low Borosilicate Amber Glass Ampoule x 2 mL (Box of 10's) | RxVAT-exempt | Anhui Changjiang Pharmaceutical Co., Ltd.China | CV Clearvue Pharma, Inc.Importer: Aglobal Care, Inc. | DRP-6647-03 | Jan 9, 2030 | |
FurogenFurosemide | 10 mg / mL Solution for Injection (IM/IV)USP Type I amber glass ampoule x 2 mL (Box of 5 ampoules x 2 mL: Box of 10 mL ampoules x 2 mL) | RxVAT-exempt | Farbe Firma Pvt. Ltd.India | Genzen Pharmaceutical TradingImporter: AMB HK Enterprises Inc.Trader: Medicon Lifesciences | DRP-12524-02 | Aug 26, 2027 | |
FurogenFurosemide | 10 mg/mL (20 mg/2mL) Solution for Injection (IM/IV)Clear Colorless Glass Ampoule x 2 mL in PVC Tray (Box of 10’s) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Genzen Pharmaceutical TradingImporter: Amb Hk Enterprises Inc. | DRP-14959-01 | Feb 27, 2029 | |
FurojoFurosemide | 10mg/mL (20mg/2mL) Solution for Injection (I.M./I.V.)2mL USP Type I Amber Glass Ampoule (Box of 10’s) | RxVAT-exempt | Swiss Parenterals Ltd. (Block-B)India | Joasha Pharmaceutical Inc.Importer: Ambica International Corporation | DRP-7383-03 | Oct 4, 2027 | |
FuromidexFurosemide | 10 mg/mL (20 mg/2 mL) Solution for Injection (I.M./I.V.)2 mL USP Type I Amber Glass Ampoule (Box of 10's) | RxVAT-exempt | Swiss Parenterals Ltd.India | Ambitech Biopharmaceuticals Inc.Importer: Ambica International Corporation | DRP-7383-01 | Oct 4, 2027 | |
FuronavFurosemide | 10 mg/mL (20 mg/2 mL) Solution for Injection (IM/IV)USP Type I Amber Colored Glass Ampoule x 2 mL (Box of 10's) | RxVAT-exempt | Harmann Pharmaceutical Laboratories (Pvt) Ltd.Pakistan | Jn Carlo Pharmaceuticals DistributorImporter: Raquel-Abbas Pharmaceuticals & General Merchandise | DRP-4423-03 | Aug 16, 2030 | |
FuronexFurosemide | 10 mg/mL Solution for Injection (IM/IVUSP Type I amber colored glass vial with grey bromobutyl serum stopper and red colored aluminum flip-off seal x 2 mL (Box of 25 vials) | RxVAT-exempt | Aspiro Pharma LimitedIndia | Camber Pharmaceutical Inc. | DRP-11328 | Mar 2, 2027 | |
FuronovaFurosemide | 10 mg/ml Solution for Injection (IM/IV)USP Type I amber glass ampoule x 2mL (Box of 10 ampoules in plastic tray) | RxVAT-exempt | Steril-Gene Life Sciences (P) Ltd.India | Medinova Pharmaceutical, Inc. | DRP-11980 | May 25, 2027 | |
FuroradFurosemide | 10 mg/mL (20 mg/2 mL) Solution for Injection (I.M./I.V.)Brown Low Borosilicate Glass Ampoule x 2 mL (net content) (Box of 10's) | RxVAT-exempt | Furen Pharmaceutical Group Co., Ltd.China | HLM Pharmaceutical Inc.Importer: Euro-Care Products Philippines | DRP-8351-06 | Aug 22, 2029 | |
FurosamFurosemide | 10 mg/mL (20 mg/2mL) Solution for Injection (IM/IV)Clear Colorless Glass Ampoule x 2 mL in PVC Tray (Box of 10's) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-14959 | Feb 27, 2029 | |
FurosanFurosemide | 10 mg/mL Solution for Injection (IM/IV)Type II Amber Glass Ampoule x 2 mL (Box of 10's) | RxVAT-exempt | Shandong Xier Kangtai Pharmaceutical Co., Ltd.China | Sannovex Pharmaceutical Distributor | DRP-2066 | Jul 1, 2029 | |
FurosaveFurosemide | 10 mg/mL (20 mg/mL) Solution for Injection (IM/IV)Type I Low Borosilicate Amber Glass Ampoule x 2 mL (Box of 10's) | RxVAT-exempt | Anhui Changjiang Pharmaceutical Co., Ltd.China | Savelink Pharma and Trading Co.Importer: Aglobal Care, Inc. | DRP-6647-05 | Jan 9, 2030 | |
FuroSaveFurosemide | 10mg/mL (20mg/2mL) Solution for Injection (IM/IV/SC)Type I Clear Glass Ampoule x 2mL in PVC Tray (Box of 10's) | RxVAT-exempt | Maxitech Pharma (Pvt.) Ltd.Pakistan | Savelink Pharma And Trading Co.Importer: Accesspoint International Trading Inc. | DRP-17479-01 | Jan 8, 2031 | |
FuroscanFurosemide | 20 mg/2mL Solution for Injection (IM/IV)Type I amber glass ampoule x 2mL (Box of 100's) | RxVAT-exempt | Tai Yu Chemical & Pharmaceutical Co., Ltd.Taiwan | Phoenix Pharmaceutical, Inc. | DR-XY33547 | Jul 9, 2027 | |
FuroseFurosemide | 10 mg/mL (20 mg/mL) Solution for Injection (IM/IV)Type I Low Borosilicate Amber Glass Ampoule x 2 mL (Box of 10's) | RxVAT-exempt | Anhui Changjiang Pharmaceutical Co., Ltd.China | Aglobal Care, Inc. | DRP-6647 | Jan 9, 2030 | |
Furosel-DIUFurosemide | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Pharmakon Biotec Inc. | DRP-15290 | Jun 10, 2029 | |
FurosetabFurosemide | 40 mg TabletAlu/Clear PVC Blister Pack x 10’s Box of 100’s | RxVAT-exempt | West-Coast Pharmaceutical Works Ltd.India | Diafarm Inc.Importer: Ambica International Corporation | DRP-6138-01 | May 6, 2030 | |
FurotalisFurosemide | 10 mg/mL Solution for Injection2 mL USP Type I Amber Glass Ampoule x 10 per plastic tray (Box of 10's) | RxVAT-exempt | Vitalis S.A.C.I. - Plant 8Colombia | Pan-Ject Pharmaceuticals CorpTrader: Vitalis S.A.C.I. | DRP-7122 | Sep 9, 2028 | |
FurovintFurosemide | 10 mg / mL (20 mg / 2 mL) Solution for Injection (I.V./I.M.)USP Type I Amber coloured glass ampoule x 2 mL (Box of 10's) | RxVAT-exempt | Makcur Laboratories LimitedIndia | Vintel Med EnterprisesImporter: Afree Pharmaceutical Distribution Corp. | DRP-14389-01 | Aug 31, 2028 | |
FuroweeFurosemide | 10 mg/mL (20 mg/2 mL) Solution for Injection (I.M./I.V.)Brown Low Borosilicate Glass Ampoule x 2 mL (net content) (Box of 10's) | RxVAT-exempt | Furen Pharmaceutical Group Co., Ltd.China | Asianmeds, Inc.Importer: Euro-Care Products Philippines | DRP-8351-08 | Aug 22, 2029 | |
FurowellFurosemide | 10 mg/mL (20 mg/2 mL) Solution for Injection (I.M./I.V.)2 mL USP Type I Amber Glass Ampoule (Box of 10 ampoules mounted in clear and colorless PVC Tray) | RxVAT-exempt | Swiss Parenterals Ltd.India | GIC Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-7383-02 | Oct 4, 2027 | |
FuroxcelFurosemide | 10 mg/mL (20 mg/2 mL) Solution for Injection (IM/IV)USP Type I amber glass ampoule x 2 mL (Box of 10's) | RxVAT-exempt | Ta Fong Pharmaceutical Co., Ltd.Taiwan | Excelpharm CorporationImporter: GPC Geo Pharma Corporation | DR-XY45111 | Feb 26, 2031 | |
FuroxideFurosemide | 10 mg/mL (20 mg/2 mL) Solution for Injection (IM/IV)USP Type I Amber Colored Glass Ampoule x 2 mL (Box of 10's) | RxVAT-exempt | Harmann Pharmaceutical Laboratories (Pvt.) Ltd.Pakistan | Raquel-Abbas Pharmaceuticals & General Merchandise | DRP-4423 | Aug 16, 2030 | |
FurozFurosemide | 10 mg/mL Solution for Injection (IV)USP Type I amber glass ampoule x 2 mL (Box of 50's) | RxVAT-exempt | Dai Han Pharm. Co., Ltd.Republic of Korea | Ellebasy Medicale TradingImporter: JLT Pharma Inc. | DRP-11741-01 | Apr 25, 2027 | |
FusedexFurosemide | 20 mg TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Drugmaker's Laboratories, Inc.Philippines | — | DRP-5555 | Oct 11, 2031 | |
FusedexFurosemide | 40 mg TabletAlu/Clear PVC Blister pack x 20's (Box of 100's) | RxVAT-exempt | Drugmaker's Laboratories Inc.Philippines | — | DRP-5446 | Nov 11, 2030 | |
FusemFurosemide | 10mg/mL Solution for Injection (I.M./I.V.)USP Type III Amber Glass Ampoule x 2mL (Box of 10's and 100's) | RxVAT-exempt | Reyoung Pharmaceutical Co., Ltd.China | Health Saver Pharma Inc. | DRP-2028 | Aug 14, 2027 | |
FusemFurosemide | 40 mg TabletAmber PVC/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Centurion Remedies Pvt. Ltd.India | TGP Pharma Inc.Importer: Philgen Pharmaceuticals Inc. | DRP-3567 | Aug 18, 2029 | |
FusimexFurosemide | 10mg/mL Solution for Injection (IM/IV)Amber Glass Ampoule x 2mL (Box of 10's) | RxVAT-exempt | SM Pharmaceutical (M) Sdn. Bhd.Malaysia | Importer: PNF Pharmaceutical, Inc. | DRP-3373 | Nov 7, 2027 | |
FusoranFurosemide | 10 mg /mL Solution for Injection (IM/IV)USP Type I Amber Glass Ampoule x 2 ml (Box of 10’s) | RxVAT-exempt | Umedica Laboratories Pvt. Ltd.India | Orange Biotec Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-6165-01 | May 22, 2031 | |
IndiurexFurosemide | 40 mg TabletRed-colored PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Towa Pharmaceutical Co., Ltd.Japan | Importer: Crisdy-Na Drug CorporationTrader: Crisdy-Na Drug Corporation | DR-XY38730 | Nov 18, 2031 | |
KenzamideFurosemide | 40 mg TabletAlu/PVC Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Baroque Pharmaceuticals Pvt. Ltd.India | Bell-Kenz Pharma, Inc.Importer: AMB HK Enterprises, Inc. | DRP-17119-01 | Oct 1, 2030 | |
KenzamideFurosemide | 40 mg TabletAlu/Clear PVC Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | Bell-Kenz Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-4689-01 | Sep 22, 2031 | |
Khrizsix 20Furosemide (as sodium) | 10 mg/mL Solution for Inject (IM/IV)Amber Glass Ampoule x 2 mL (Box of 5 ampoules in a tray) | RxVAT-exempt | Merit Organics Ltd.India | Khriz Pharma Trading Inc.Trader: Lob International | DR-XY49196 | Sep 10, 2029 | |
KosixFurosemide | 10 mg/mL Solution For Injection (I.M./I.V.)USP Type I amber glass ampoule x 2 mL (Box of 5 ampoules x 2mL; Box of 10 ampoules x 2mL) | RxVAT-exempt | Farbe FirmaIndia | Amb HK Enterprises Inc.Importer: AMB HK Enterprises Inc. | DRP-12524 | Aug 26, 2027 | |
LasiflowFurosemide | 40 mg TabletAlu/PVC blister pack x 10's (Box of 100's) | RxVAT-exempt | Baroque Pharmaceuticals Pvt. Ltd.India | AMB HK Enterprises Inc. | DRP-17119 | Oct 1, 2030 | |
LasixFurosemide (As Sodium) | 10 mg/mL (20 mg/2 mL) Solution For Injection (I.V./I.M.)Amber Ampoule with Pink OPC point x 2 mL in a white blister tray made of polystyrene (Box of 5's) | RxVAT-exempt | Sanofi İlaç Sanayi ve Ticaret Anonim ŞirketiTurkey | Sanofi-Aventis Philippines, Inc. | DR-1111 | Jul 17, 2031 | |
LasixFurosemide | 40 mg TabletGreen transparent PVC/Alu Blister Pack x 15's (Box of 150's) | RxVAT-exempt | Handok Inc.Republic of Korea | Sanofi-Aventis Philippines, Inc. | DR-1110 | Apr 15, 2028 | |
LazicareFurosemide | 10 mg/mL (20mg/2mL) Solution for Injection (I.M./I.V.)Brown Low Borosilicate Glass Ampoule x 2 mL (net content) Box of 10's | RxVAT-exempt | Furen Pharmaceutical Group Co., Ltd.China | Euro-Care Products Philippines | DRP-8351 | Aug 22, 2029 | |
LazimedFurosemide | 10 mg/mL (20 mg/2 mL) Solution for Injection (IM/IV)Brown Low Borosilicate Glass Ampoule x 2 mL (net content) (Box of 10's) | RxVAT-exempt | Furen Pharmaceutical Group Co., Ltd.China | Asianmeds, Inc.Importer: Euro-Care Products Philippines | DRP-8351-02 | Aug 22, 2029 | |
LoopreticFurosemide | 10 mg / mL Solution for Injection (IM/IV)USP Type I amber glass ampoule x 2 mL (Box of 50's) | RxVAT-exempt | Dai Han Pharm Co., Ltd.Republic of Korea | Pharmasia-Cuvest IncorporatedImporter: JLT Pharma, Inc. | DRP-11741-02 | Apr 25, 2027 | |
MD-UreticFurosemide | 10 mg/mL (20 mg/2 mL) Solution for Injection (IM/IV)Brown Low Borosilicate Glass Ampoule x 2 mL (net content) (Box of 10's) | RxVAT-exempt | Furen Pharmaceutical Group Co., Ltd.China | MDB Pharma TradingImporter: Euro-Care Products Philippines | DRP-8351-04 | Aug 22, 2029 | |
NoneFurosemide | 10 mg/mL (20 mg/2 mL) Solution for Injection (I.V./I.M.)USP Type I Amber coloured glass ampoule x 2 mL (Box of 10's) | RxVAT-exempt | Makcur Laboratories LimitedIndia | Reta DrugImporter: Afree Pharmaceutical Distribution Corp. | DRP-14389-02 | Aug 31, 2028 | |
NoneFurosemide | 10 mg/mL Solution for Injection (I.M./I.V.)Amber ampoule x 2 mL (Box of 10's) | RxVAT-exempt | Karnataka Antibiotics & Pharmaceuticals LimitedIndia | Phil. Pharmawealth, Inc. | DR-XY28303 | Feb 10, 2030 | |
NoneFurosemide | 20 mg TabletAlu/PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Am-Europharma CorporationPhilippines | — | DRP-2892 | Apr 11, 2032 | |
PisamorFurosemide | 40 mg TabletAlu/PVC Blister Pack x 10’s Box of 100’s | RxVAT-exempt | Flamingo Pharmaceuticals Ltd.India | Hexagon Pharmaceuticals | DR-XY28028 | Nov 8, 2027 | |
PrimusixFurosemide | 10 mg/mL (20 mg/2 mL) Solution for Injection (I.M./I.V.)2 mL USP Type I Amber Glass Ampoule (Box of 10's) | RxVAT-exempt | Swiss Parenterals Ltd.India | Primus Medicus Distributors Inc.Importer: Ambica International Corporation | DRP-7383 | Oct 4, 2027 | |
Q-ReticFurosemide | 10 mg/mL (20 mg/2 mL) Solution for Injection (IM/IV)Brown Low Borosilicate Glass Ampoule x 2 mL (net content) (Box of 10's) | RxVAT-exempt | Furen Pharmaceutical Group Co., Ltd.China | Quad-Gen PharmaceuticalsImporter: Euro-Care Products Philippines | DRP-8351-03 | Aug 22, 2029 | |
RahsemideFurosemide | 10mg/mL (20mg/2mL) Solution for Injection (IM/IV/SC)Type I Clear Glass Ampoule x 2mL in PVC Tray (Box of 10's) | RxVAT-exempt | Maxitech Pharma (Pvt) Ltd.Pakistan | Accesspoint International Trading Inc. | DRP-17479 | Jan 8, 2031 | |
RasitolFurosemide | 10 mg/mL Solution for Injection (IV)Type I Amber Glass Ampoule x 2 mL (Box of 10's) | RxVAT-exempt | Yung Shin Pharmaceuticals Ind. Co., Ltd. - Taichung Youth FactoryR.O.C | Yung Shin (Philippines),Inc. | DRP-9959 | Jun 24, 2029 | |
RofunilFurosemide | 10 mg/mL Solution for Injection (IM/IV)Amber Glass Ampoule x 2 mL (Box of 10's) | RxVAT-exempt | SM Pharmaceutical (M) Sdn. Bhd.Malaysia | Duopharma Trade Phils., Inc.Importer: PNF Pharmaceutical, Inc. | DRP-3373-01 | Nov 7, 2027 | |
RoseroFurosemide | 10 mg/mL (20 mg/2 mL) Solution For Injection (IM/IV)USP Type 1 amber glass ampoule x 2 mL (Box of 10's) | RxVAT-exempt | Steril-Gene Life Sciences (P) Ltd.India | Aglobal Care, Inc. | DRP-12913 | Nov 4, 2027 | |
Siti-FuroseFurosemide | 10mg/mL (20mg/2mL) Solution for Injection (IM/IV)Low Borosilicate Glass Ampoule x 2mL (Box of 10's) | RxVAT-exempt | TianJin King York Group HuBei TianYao Pharmaceutical Co., Ltd.China | Sahar International Trading Inc.Trader: Zlf Pharmaceutical Limited | DR-XY49317 | Jan 10, 2030 | |
Urinasaph-F20Furosemide | 10 mg/mL (20 mg/ 2 mL) Solution For Injection (IM/IV)Clear Glass Ampoule x 2 mL (Box of 10's) | RxVAT-exempt | Kilitch Drugs (India) Ltd.India | Nelpa Lifesciences, Inc. | DRP-13050 | Nov 22, 2027 | |
UromidFurosemide | 40 mg TabletAlu/Clear PVC Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises Inc. | DRP-4689 | Sep 6, 2030 | |
VarmodFurosemide | 10 mg/mL Solution for Injection (IM/IV)Type I Amber Glass Ampoule x 2 mL (Box of 10's) | RxVAT-exempt | SYNCOM FORMULATIONS (INDIA) LTD.India | ARVINCARE PHARMA INC. | DRP-496 | Jan 12, 2028 | |
(no brand name)Furosemide | 10mg/mL Solution for InjectionUSP Type I Amber Glass Ampoule x 2mL (Box of 100's) | RxVAT-exempt | Atlantic Laboratories Corporation LimitedThailand | Phil Pharmawealth, Inc. | DR-XY27826 | Sep 10, 2027 | |
(no brand name)Furosemide | 10mg/mL Solution For Injection (IM/IV)USP Type I amber glass ampoule x 2 mL (Box of 50's) | RxVAT-exempt | Dai Han Pharm Co., Ltd.Korea | JLT Pharma, Inc. | DRP-11741 | Apr 25, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Injection: Furosemide Injection, USP is supplied as a sterile, colorless solution as 40 mg/4 mL (10 mg/mL) in a single-dose vial Injection: Furosemide Injection, USP is supplied as a sterile, colorless solution as 40 mg/4 mL (10 mg/mL) in a single-dose vial (3
Warnings/Precautions
- Fluid, Electrolyte, and Metabolic Abnormalities: Monitor serum electrolytes, CO2, BUN, creatinine, glucose, and uric acid (5.1)
- Worsening Renal Function: Monitor for dehydration and azotemia. (5.2)
- Ototoxicity: Avoid rapid injection and higher than recommended doses. (5.3, 7.1)
- Acute Urinary Retention: Monitor patients with symptoms of urinary retention. (5.4)
5.1 Fluid, Electrolyte, and Metabolic Abnormalities
5.1 Fluid, Electrolyte, and Metabolic Abnormalities Furosemide may cause fluid, electrolyte, and metabolic abnormalities such as hypovolemia, hypokalemia, azotemia, hyponatremia, hypochloremic alkalosis, hypomagnesemia, hypocalcemia, hyperglycemia, or hyperuricemia, particularly in patients receiving higher doses, patients with inadequate oral electrolyte intake, and in elderly patients. Excessive diuresis may cause dehydration and blood volume reduction with circulatory collapse and possibly vascular thrombosis and embolism, particularly in elderly patients.
Serum electrolytes, CO2, BUN, creatinine, glucose, and uric acid should be monitored frequently during furosemide therapy. In patients with hepatic cirrhosis and ascites, sudden alterations of fluid and electrolyte balance may precipitate hepatic encephalopathy and coma. Treatment in such patients is best initiated in the hospital with small doses and careful monitoring of the patient's clinical status and electrolyte balance.
5.2 Worsening Renal Function
5.2 Worsening Renal Function Furosemide can cause dehydration and azotemia. If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, furosemide should be discontinued [see Clinical Pharmacology (12.3)]. Furosemide use in the first year of life, especially in patients born pre-term, may precipitate nephrocalcinosis/nephrolithiasis.
Therefore renal function must be monitored and renal ultrasonography performed in this age group [see Use in Specific Populations (8.4)].
5.3 Ototoxicity
5.3 Ototoxicity Cases of tinnitus and reversible or irreversible hearing impairment and deafness have been reported. Reports usually indicate that furosemide ototoxicity is associated with rapid injection, severe renal impairment, the use of higher than recommended doses, hypoproteinemia or concomitant therapy with aminoglycoside antibiotics, ethacrynic acid, or other ototoxic drugs.
If the physician elects to use high-dose parenteral therapy, controlled intravenous infusion is advisable (for adults, an infusion rate not exceeding 4 mg furosemide per minute has been used) [see Drug Interactions (7.1)]. Hearing loss in neonates, including premature neonates has been associated with the use of Furosemide injection [see Use in Specific Populations (8.4)].
5.4 Acute Urinary Retention
5.4 Acute Urinary Retention In patients with severe symptoms of urinary retention (because of bladder emptying disorders, prostatic hyperplasia, urethral narrowing), the administration of furosemide can cause acute urinary retention related to increased production and retention of urine. Thus, these patients require careful monitoring, especially during the initial stages of treatment.
Drug interactions
- Aminoglycoside antibiotics: Increased potential ototoxicity of the antibiotics. Avoid combination (7.1)
- Ethacrynic acid: Risk of ototoxicity. Avoid combination (7.1)
- Salicylates: Risk of salicylate toxicity (7.1)
- Cisplatin and nephrotoxic drugs: Risk of ototoxicity and nephrotoxicity (7.1)
- Lithium: Risk of lithium toxicity (7.1)
- Renin-angiotensin inhibitors: Increased risk of hypotension and renal failure. (7.1)
- Adrenergic blocking drugs: Risk of potentiation (7.1)
- Drugs undergoing renal tubular secretion: Risk of toxicity potentiation (7.1)
7.1 Effects of Furosemide on Other Drugs
7.1 Effects of Furosemide on Other Drugs Drug/Substance Class or Name Drug Interaction Effect Recommendations Aminoglycoside antibiotics Furosemide may increase the ototoxic potential of aminoglycoside antibiotics, especially in the presence of impaired renal function [see Warnings and Precautions (5.3)]. Avoid combination except in life-threatening situations.
Ethacrynic acid Possibility of ototoxicity [see Warnings and Precautions (5.3)]. Avoid concomitant use with ethacrynic acid. Salicylates May experience salicylate toxicity at lower doses because of competitive renal excretory sites. Monitor for symptoms of salicylate toxicity. Cisplatin There is a risk of ototoxic effects if cisplatin and furosemide are given concomitantly [see Warnings and Precautions (5.3)].
Cisplatin and nephrotoxic drugs Nephrotoxicity Administer furosemide at lower doses and with positive fluid balance when used to achieve forced diuresis during cisplatin treatment. Monitor renal function. Paralytic agents Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine.
Monitor for skeletal muscle effect. Lithium Furosemide reduces lithium’s renal clearance and add a high-risk of lithium toxicity. Avoid concomitant use with lithium. Angiotensin converting enzyme inhibitors or angiotensin II receptor blockers May lead to severe hypotension and deterioration in renal function, including renal failure.
Monitor for changes in blood pressure and renal function and interrupt or reduce the dosage of furosemide, angiotensin converting enzyme inhibitors, or angiotensin receptor blockers if needed. Antihypertensive drugs Furosemide may add to or potentiate the therapeutic effect of other antihypertensive drugs. Monitor for changes in blood pressure and adjust the dose of other antihypertensive drugs if needed.
Adrenergic blocking drugs or peripheral adrenergic blocking drugs Potentiation occurs. Monitor for changes in blood pressure and adjust the dose of adrenergic blocking drugs if needed. Norepinephrine Furosemide may decrease arterial responsiveness (vasoconstricting effect) to norepinephrine. Monitor blood pressure (or mean arterial pressure).
Chloral hydrate In isolated cases, intravenous administration of furosemide within 24 hours of taking chloral hydrate may lead to flushing, sweating attacks, restlessness, nausea, increase in blood pressure, and tachycardia. Concomitant use with chloral hydrate is not recommended. Methotrexate and other drugs undergoing renal tubular secretion Furosemide may decrease renal elimination of other drugs that undergo tubular secretion.
High-dose treatment of furosemide may result in elevated serum levels of these drugs and may potentiate their toxicity. Monitor serum levels of drugs undergoing renal tubular secretion and adjust the dose if needed. Cephalosporin Furosemide can increase the risk of cephalosporin-induced nephrotoxicity even in the setting of minor or transient renal impairment.
Monitor for changes in renal function. Cyclosporine Increased risk of gouty arthritis secondary to furosemide-induced hyperuricemia and cyclosporine impairment of renal urate excretion. Monitor serum urate levels. Thyroid hormones High-doses (> 80 mg) of furosemide may inhibit the binding of thyroid hormones to carrier proteins and result in transient increase in free thyroid hormones, followed by an overall decrease in total thyroid hormone levels.
Monitor the total thyroid hormone levels.
7.2 Effects of Other Drugs on Furosemide
7.2 Effects of Other Drugs on Furosemide Drug/Substance Class or Name Drug Interaction Effect Recommendations Phenytoin Interferes directly with renal action of furosemide. Monitor diuretic effects of furosemide and adjust the dose of furosemide if needed. Methotrexate and other drugs undergoing renal tubular secretion May reduce the effect of furosemide.
High-dose treatment of methotrexate and these other drugs may result in elevated serum levels of furosemide and may potentiate the toxicity of furosemide. Monitor for enhanced toxicity of furosemide. Indomethacin Coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis.
Indomethacin may also affect plasma renin levels, aldosterone excretion, and renin profile evaluation. Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.
Adverse reactions
Adverse reactions (US label) US FDA label
6 ADVERSE REACTIONS The following adverse reactions are described elsewhere in the labeling: Fluid, Electrolyte, and Metabolic Abnormalities [see Warnings and Precautions (5.1)] Ototoxicity [see Warnings and Precautions (5.3)] The following adverse reactions associated with the use of furosemide were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Adverse reactions are categorized below by organ system and listed by decreasing severity. Gastrointestinal System Reactions: pancreatitis, jaundice (intrahepatic cholestatic jaundice), increased liver enzymes, anorexia, oral and gastric irritation, cramping, diarrhea, constipation, nausea, vomiting. Systemic Hypersensitivity Reactions: severe anaphylactic or anaphylactoid reactions (e.g., with shock), systemic vasculitis, interstitial nephritis, necrotizing angiitis.
Central Nervous System Reactions: tinnitus and hearing loss, paresthesias, vertigo, dizziness, headache, blurred vision, xanthopsia. Hematologic Reactions: aplastic anemia, thrombocytopenia, agranulocytosis, hemolytic anemia, leukopenia, anemia, eosinophilia. Dermatologic-Hypersensitivity Reactions: toxic epidermal necrolysis, Stevens-Johnson Syndrome, erythema multiforme, drug rash with eosinophilia and systemic symptoms, acute generalized exanthematous pustulosis, exfoliative dermatitis, bullous pemphigoid, purpura, photosensitivity, rash.
Cardiovascular Reactions: orthostatic hypotension, increase in cholesterol and triglyceride serum levels. Other Reactions: glycosuria, muscle spasm, weakness, restlessness, urinary bladder spasm, thrombophlebitis, transient injection site pain following intramuscular injection, fever. Most common adverse reactions are related to fluid and electrolyte imbalance (6) To report SUSPECTED ADVERSE REACTIONS, contact Hikma Pharmaceuticals USA Inc. at 1-877-845-0689 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Available data from published observational studies, case reports, and postmarketing reports, from decades of use, have not demonstrated a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes with furosemide use during pregnancy. Untreated congestive heart failure and cirrhosis of the liver can lead to adverse outcomes for the mother and the fetus (see Clinical Considerations).
In animal reproduction studies, furosemide has been shown to cause unexplained maternal deaths and abortions in rabbits when administered orally during organogenesis at 4 times a human i.v. dose of 80 mg based on body surface area (BSA) and oral bioavailability corrections, presumably secondary to volume depletion (see Data). The estimated background risk for major birth defects and miscarriage for the indicated populations is unknown.
All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in the clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Disease-Associated Maternal and/or Embryo/Fetal Risk Pregnant women with congestive heart failure are at increased risk for pre-term birth.
Stroke volume and heart rate increase during pregnancy, increasing cardiac output, especially during the first trimester. Clinical classification of heart disease may worsen with pregnancy and lead to maternal death and/or stillbirth. Closely monitor pregnant patients for destabilization of their heart failure. Pregnant women with symptomatic cirrhosis generally have poor outcomes including hepatic failure, variceal hemorrhage, pre-term delivery, fetal growth restriction and maternal death.
Outcomes are worse with coexisting esophageal varices. Pregnant women with cirrhosis of the liver should be carefully monitored and managed accordingly. Data Animal Data The effects of furosemide on embryonic and fetal development and on pregnant dams were studied in mice, rats and rabbits. Furosemide caused unexplained maternal deaths and abortions in the rabbit at the lowest dose of 25 mg/kg (approximately 4 times a human i.v. dose of 80 mg based on BSA and oral bioavailability corrections).
In another study, a dose of 50 mg/kg (approximately 7 times a human i.v. dose of 80 mg based on BSA and oral bioavailability corrections) also caused maternal deaths and abortions when administered to rabbits between Days 12 and 17 of gestation. In a third study, none of the pregnant rabbits survived an oral dose of 100 mg/kg.
Data from the above studies indicate fetal lethality that can precede maternal deaths. The results of the mouse study and one of the three rabbit studies also showed an increased incidence and severity of hydronephrosis (distention of the renal pelvis and, in some cases, of the ureters) in fetuses of treated dams as compared with the incidence of fetuses from the control group.
Mechanism of action
12.1 Mechanism of Action Furosemide inhibits primarily the reabsorption of sodium and chloride not only in the proximal and distal tubules but also in the loop of Henle. The high degree of efficacy is largely due to this unique site of action. The action on the distal tubule is independent of any inhibitory effect on carbonic anhydrase and aldosterone.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics The onset of diuresis following intravenous administration is within 5 minutes and somewhat later after intramuscular administration. The peak effect occurs within the first half hour. The duration of diuretic effect is approximately 2 hours.
Pharmacokinetics
Elimination The terminal half-life of furosemide is approximately 2 hours.
Excretion Significantly more furosemide is excreted in urine following the intravenous injection than after the tablet or oral solution.
Furosemide is predominantly excreted unchanged in the urine.
The renal clearance of furosemide after intravenous administration in older healthy male subjects (60 to 70 years of age) is statistically significantly smaller than in younger healthy male subjects (20 to 35 years of age).
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Distribution Furosemide is extensively bound to plasma proteins, mainly to albumin. Plasma concentrations ranging from 1 to 400 mcg/mL are 91 to 99% bound in healthy individuals. The unbound fraction averages 2.3 to 4.1% at therapeutic concentrations. Elimination The terminal half-life of furosemide is approximately 2 hours.
Metabolism Recent evidence suggests that furosemide glucuronide is the only or at least the major biotransformation product of furosemide in man. Excretion Significantly more furosemide is excreted in urine following the intravenous injection than after the tablet or oral solution. Specific Populations Geriatric Patients Furosemide binding to albumin may be reduced in elderly patients.
Furosemide is predominantly excreted unchanged in the urine. The renal clearance of furosemide after intravenous administration in older healthy male subjects (60 to 70 years of age) is statistically significantly smaller than in younger healthy male subjects (20 to 35 years of age). The initial diuretic effect of furosemide in older subjects is decreased relative to younger subjects [see Use in Specific Populations (8.5)].
Pediatric Patients Based on PK results obtained from 51 premature infants (23-29 weeks gestational age (GA)) receiving repeated doses up to 4 times the maximum recommended total daily dose for intravenous (IV) administration (or 8 times the maximum recommended total daily dose for enteral administration), body weight and postnatal age were found to have an impact on furosemide clearance. Median clearance (normalized by dosing weight) was observed to increase from 8.9 (range: 2.1-21.2) ml/h/kg in infants with postnatal age (PNA) <30 days to 25.3 (range: 8.3 to 44.2) ml/h/kg in infants with PNA >30 days.
In addition, higher clearance was observed in infants with higher body weight. Bioavailability of enteral dose compared to IV dose was estimated to be around 79%. Patients with Renal Impairment One study in six subjects demonstrated that the combination of furosemide and acetylsalicylic acid temporarily reduced creatinine clearance in patients with chronic renal insufficiency.
There are case reports of patients who developed increased BUN, serum creatinine and serum potassium levels, and weight gain when furosemide was used in conjunction with NSAIDs.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Furosemide 10 mg/mL, 2 mL Ampule | ₱3.93–₱20.00Reference ₱5.43 | per ampule | DPRI procurement range |
| Furosemide 20 mg Tablet | ₱0.78–₱1.30Reference ₱1.00 | per tablet | DPRI procurement range |
| Furosemide 40 mg Tablet | ₱0.60–₱1.90Reference ₱1.50 | per tablet | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Furosemide |
| PNF listing | Oral: 20 mg and 40 mg tabletRestrictions: List B: in vivo bioequivalence studies required (PNF code B) |
| PNF listing | Inj.: 10 mg/mL, 2 mL ampul (IM, IV) |
| PNF listing | Inj.: 10 mg/mL, 25 mL ampul (IV infusion) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Furosemide · Civica, Inc. [US FDA-approved label, version 2, October 31, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6d9caaab-d874-4cf1-b9fe-408452a18998
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .



